This is a renewal application for The Pittsburgh Pediatric Rheumatology Training Grant. Pediatric rheumatology focuses on musculoskeletal and autoimmune diseases of childhood. Serving this population of children are 237 board-certified pediatric rheumatologists in the United States (as of 2008). All but a handful of these are clinicians who do not engage in research. As a result, few pediatric rheumatologists have had research mentorship and they lack the skills to perform cutting edge research. The Division of Pediatric Rheumatology at the Children's Hospital of Pittsburgh, with substantial and sustained institutional support, has endeavored to create a national center of excellence offering comprehensive, state-of-the-art clinical care, educational programs, and competitive research involving clinical, translational, and basic sciences. Our Training Program is one of only two NIH-funded training programs dedicated to pediatric rheumatology. One of our central missions is to educate a new generation of academic pediatric rheumatologists who can play a leading role in the specialty as physician scientists. The goal is to provide a prime source of well- trained M.D. academic pediatric rheumatologists and Ph.D. scientists to serve the national need for cutting- edge research in the pediatric rheumatic diseases. To achieve this mission, we seek to provide, within a single center, the research role models, mentorship, and rich environment necessary for nurturing such individuals and ensuring their success. Support is requested to continue the current number of trainees in our program, currently four trainees per year, in order to provide two new trainees per year and two years of support for each trainee. The trainees will consist of two types of individuals. At least 75% will be pediatric rheumatology M.D. fellows who have completed a first year of clinical training. Following a first year of intensive clinical training, they will select a mentor from among the program faculty in order to gain exceptional research experience that will be used as the basis of an independent academic career. Up to 25% will be Ph.D. trainees who desire to focus their research careers in pediatric rheumatology. They will select a mentor from among the faculty who study the pediatric rheumatic diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32AR052282-10
Application #
8461878
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Program Officer
Wang, Yan Z
Project Start
2005-05-01
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
10
Fiscal Year
2013
Total Cost
$178,358
Indirect Cost
$14,066
Name
University of Pittsburgh
Department
Pediatrics
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Ardalan, Kaveh; Zigler, Christina K; Torok, Kathryn S (2016) Predictors of Longitudinal Quality of Life in Pediatric Localized Scleroderma. Arthritis Care Res (Hoboken) :
Way, Emily E; Trevejo-Nunez, Giraldina; Kane, Lawrence P et al. (2016) Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor. Sci Rep 6:30384
Poff, S; Li, S C; Kelsey, C E et al. (2016) Durometry as an outcome measure in juvenile localized scleroderma. Br J Dermatol 174:228-30
Niehaus, Jason Z; Miedel, Mark T; Good, Misty et al. (2015) SERPINB12 Is a Slow-Binding Inhibitor of Granzyme A and Hepsin. Biochemistry 54:6756-9
Niehaus, Jason Z; Good, Misty; Jackson, Laura E et al. (2015) Human SERPINB12 Is an Abundant Intracellular Serpin Expressed in Most Surface and Glandular Epithelia. J Histochem Cytochem 63:854-65
Poff, Sarah; Li, Suzanne C; Kelsey, Christina et al. (2014) A48: Durometer Measures Discriminate Affected versus Normal Skin in Pediatric Localized Scleroderma. Arthritis Rheumatol 66 Suppl 3:S72-3
Campfield, Brian T; Nolder, Christi L; Marinov, Anthony et al. (2014) Follistatin-like protein 1 is a critical mediator of experimental Lyme arthritis and the humoral response to Borrelia burgdorferi infection. Microb Pathog 73:70-9
Aggarwal, Rohit; Cassidy, Elaine; Fertig, Noreen et al. (2014) Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73:227-32
Way, Emily E; Chen, Kong; Kolls, Jay K (2013) Dysregulation in lung immunity - the protective and pathologic Th17 response in infection. Eur J Immunol 43:3116-24
Gorelik, Mark; Fall, Ndate; Altaye, Mekibib et al. (2013) Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 40:1191-9

Showing the most recent 10 out of 20 publications